Oncology Nutrition Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Specialized Formula is the fastest growing sector, North America is the largest market

The Global Oncology Nutrition Market is projected to expand significantly, rising from USD 3.01 Billion in 2025 to USD 5.03 Billion by 2031, demonstrating an 8.93% Compound Annual Growth Rate. This market encompasses specialized clinical dietary products, such as enteral feeds and oral nutritional supplements, designed to counteract the complex metabolic changes and cachexia associated with cancer and its treatments. Growth is primarily driven by the increasing incidence of malignancies and the growing clinical recognition that nutritional support is crucial for improving treatment tolerance and patient recovery. For instance, the American Cancer Society estimated over 2 million new cancer diagnoses in the U.S.

alone in 2025, highlighting a global increase in disease burden demanding comprehensive supportive care.However, the market's expansion faces a substantial hurdle due to inconsistent reimbursement policies and limited insurance coverage for medical nutrition products across different countries. This financial constraint often makes these vital formulations inaccessible to patients in price-sensitive regions and hinders their wider adoption outside of hospital environments. Consequently, manufacturers are continually challenged to prove the pharmacoeconomic benefits of their products to payers and healthcare authorities to secure adequate coverage and ensure sustained market growth.

Market Drivers

The primary catalyst for the Global Oncology Nutrition Market's growth is the rising global prevalence of cancer and the critical issue of malnutrition that frequently accompanies it. As cancer rates climb, malnutrition remains a widespread comorbidity profoundly affecting treatment outcomes and patient survival, thereby necessitating aggressive nutritional interventions.

A systematic review published by the National Institutes of Health in July 2025 reported severe malnutrition in 19.3% of cancer patients, with rates reaching as high as 85% in specific groups like those with pancreatic cancer, underscoring the urgent clinical demand for specialized formulations to combat cachexia and stabilize patient weight during intensive cancer therapies.Furthermore, the market is experiencing a notable structural shift towards home-based enteral feeding and outpatient care.

Healthcare systems are increasingly advocating for home-care settings to reduce hospital costs and enhance patients' quality of life, which in turn boosts the consumption of convenient, user-friendly nutritional solutions. This trend is reflected in commercial results; for example, Danone's 'Full Year 2024 Results' report from February 2025 indicated a 4.6% sales increase in its Specialized Nutrition segment, significantly bolstered by growth in homecare channels. Similarly, Fresenius Kabi's 'Annual Report 2024' from March 2025 highlighted its clinical nutrition business achieving approximately €2.4 billion in revenue for the fiscal year, demonstrating the substantial commercial scale of these crucial supportive care products.

Market Challenges

Inconsistent reimbursement policies and insufficient insurance coverage present a significant obstacle to the Global Oncology Nutrition Market's expansion. Despite strong clinical evidence supporting the effectiveness of specialized nutrition, many payer systems globally do not categorize these formulations as reimbursable medical necessities. This financial gap compels patients to pay out-of-pocket, severely diminishing adherence to nutritional protocols, especially in outpatient settings where insurance verification is often stringent.

As a result, the market struggles to effectively penetrate the non-hospital sector, limiting its revenue potential despite a high level of patient need.This deficiency in financial support is particularly detrimental given the widespread nutritional deficits observed among cancer patients. Data from the American Society for Parenteral and Enteral Nutrition in 2024 revealed that one-third of patients at ambulatory cancer centers were already at risk for malnutrition before starting treatment. When reimbursement mechanisms deny coverage for these vulnerable outpatients, the potential market considerably shrinks. Manufacturers are thus constrained from fully capitalizing on the demand for supportive care, as the economic burden prevents widespread product adoption among the very patient groups who need these interventions most.

Market Trends

The integration of immunonutrition is emerging as a pivotal market trend, shifting the therapeutic focus from mere caloric provision to targeted immune modulation. Clinicians are increasingly prescribing formulations enriched with specific pharmaconutrients, such as arginine, glutamine, and omega-3 fatty acids, to mitigate systemic inflammation and mucosal toxicity often caused by aggressive oncological treatments. This strategic approach aims to preserve immune function and minimize treatment interruptions, ultimately contributing to improved overall survival rates.

Supporting this clinical emphasis, CenterWatch reported in February 2025 the initiation of a Phase 3 clinical trial to assess a specialized oral immunonutrition regimen's effectiveness in reducing acute esophagitis severity in 121 lung cancer patients undergoing concurrent chemoradiotherapy.Concurrently, the market is observing a rapid increase in demand for plant-based and vegan oncology nutrition formulations.

This trend is driven by patient preferences for clean-label, non-dairy alternatives and the clinical necessity to accommodate lactose intolerance or gastrointestinal sensitivities frequently exacerbated by cancer therapies. Manufacturers are consequently reformulating standard enteral feeds to incorporate alternative protein sources, ensuring these products meet stringent medical requirements while aligning with evolving dietary preferences. The clinical viability of such innovations was validated by a prospective intervention study, reported by the National Institutes of Health in September 2025, which demonstrated that a high-energy plant-based enteral feed, formulated with a protein blend of 55% soy isolates and 45% pea isolates, provided effective long-term nutritional support and was well-tolerated by patients.

Key Market Players

• Abbott Laboratories Inc
• Nestle SA
• Fresenius Kabi AG
• B Braun SE
• Hormel Foods Corporation
• Danone SA
• MEIJI Holdings Co Ltd
• Global Health Products, Inc.
• Victus Inc
• Mead Johnson & Co LLC

Report Scope

In this report, the Global Oncology Nutrition Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Nutrition Market, by Cancer Type:

• Lung Cancer
• Head and Neck Cancer
• Stomach and Gastrointestinal Cancers
• Esophageal Cancer
• Liver Cancer
• Blood Cancer
• Others

Oncology Nutrition Market, by Nutrition:

• Enteral Nutrition
• Parenteral Nutrition

Oncology Nutrition Market, by Formula:

• Standard Formula
• Elemental Formula
• Specialized Formula

Oncology Nutrition Market, by Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Oncology Nutrition Market, by End User:

• Hospitals
• Homecare
• Specialty Clinics

Oncology Nutrition Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncology Nutrition Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.